MARKET

JNJ

JNJ

Johnson & Johnson
NYSE
239.99
+2.20
+0.93%
Pre Market: 240.22 +0.23 +0.10% 06:20 02/09 EST
OPEN
238.96
PREV CLOSE
237.79
HIGH
240.94
LOW
237.98
VOLUME
205
TURNOVER
--
52 WEEK HIGH
240.94
52 WEEK LOW
138.40
MARKET CAP
578.21B
P/E (TTM)
21.75
1D
5D
1M
3M
1Y
5Y
1D
Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study
Benzinga · 9h ago
Weekly Report: what happened at JNJ last week (0202-0206)?
Weekly Report · 11h ago
Reported Friday, Johnson & Johnson Highlighted OMNYPULSE OMNY-AF Pilot Results And VARIPULSE Data Reinforcing Favorable Safety And Efficiency Profile At 2026 AF Symposium In Boston
Benzinga · 12h ago
Johnson & Johnson (JNJ) Valuation After Strong Q4 Results And US$100b 2026 Growth Ambitions
Simply Wall St · 1d ago
What is Considered a Good Stock Dividend? 2 Healthcare Stocks That Fit the Bill.
The Motley Fool · 1d ago
Insider trades: Merck, Intel, Micron among notable names
Seeking Alpha · 2d ago
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (February 2026)
Seeking Alpha · 2d ago
Johnson & Johnson presents 12-month pilot-phase data from OMNY-AF study
TipRanks · 2d ago
More
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

Webull offers Johnson & Johnson stock information, including NYSE: JNJ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JNJ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JNJ stock methods without spending real money on the virtual paper trading platform.